Development of maraviroc, a CCR5 antagonist for treatment of HIV, using a novel tropism assay
Type
Journal articlePermalink
https://hdl.handle.net/10161/16076Published Version (Please cite this version)
10.1111/nyas.12777Publication Info
(2015). Development of maraviroc, a CCR5 antagonist for treatment of HIV, using a novel tropism
assay. Annals of the New York Academy of Sciences, 1346(1). pp. 7-17. 10.1111/nyas.12777. Retrieved from https://hdl.handle.net/10161/16076.This is constructed from limited available data and may be imprecise. To cite this
article, please review & use the official citation provided by the journal.
Collections
More Info
Show full item recordScholars@Duke
James Francis Demarest
Adjunct Assistant Professor in the Department of Immunology
I have >30 years of experience in the pre-clinical, clinical, and translational
research space. Twenty-three of those years are in the pharma R&D context where I
also gained experience in diagnostics, product commercialization and life-cycle management,
interactions with Regulatory Authorities, Key Opinion Leaders (globally), and establishment/maintenance
of public-private partnerships. My career trajectory took me from NIH (Dr. Anthony
Fauci’s laboratory), to Duke Un
Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy
Rights for Collection: Scholarly Articles
Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info